| Authors: |
Sugiyama N; Rheumatology, Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Terry FE; EpiVax, Inc., Providence, RI, United States., Gutierrez AH; EpiVax, Inc., Providence, RI, United States., Hirano T; Rheumatology, Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Hoshi M; Rheumatology, Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Mizuno Y; Rheumatology, Inflammation and Immunology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan., Martin W; EpiVax, Inc., Providence, RI, United States., Yasunaga S; Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan., Niiro H; Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan., Fujio K; Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., De Groot AS; EpiVax, Inc., Providence, RI, United States. |
